Organ transport via drones: A cold chain Indian innovation

Background and objectives Timely transport of donor organs is a critical determinant of successful transplantation because organ viability is limited by cold ischaemic time (CIT). Unmanned aerial vehicles (UAVs), commonly referred to as drones, have recently emerged as promising tools for rapid medical logistics. The present study describes the design, engineering validation, and field evaluation of a drone-compatible organ transport container capable of maintaining cold-chain conditions during aerial transport. Methods A multidisciplinary engineering framework integrating biomedical engineering, materials science and transplant logistics consultation was used to design a lightweight crash-resistant container. The system incorporates carbon fibre reinforced polymer (CFRP) with aluminium reinforcement for structural stability, phase change materials (PCMs) for passive thermal regulation, and embedded sensors for monitoring temperature and mechanical shocks. Structural simulations, laboratory drop tests, thermal stability experiments, and pilot drone flight trials were conducted to evaluate mechanical resilience and preservation performance. Results Finite element simulations demonstrated that the composite container could withstand anticipated operational loads with adequate safety margins. Drop tests from heights up to 18.3 m resulted in minimal structural deformation while the internal payload chamber remained protected. Thermal experiments confirmed that PCM-based cooling maintained preservation temperatures within 0-4 °C for more than 18 h. Drone flight trials using a hexacopter UAV confirmed stable payload handling and maintenance of cold-chain conditions during simulated transport. Interpretation and conclusions The prototype demonstrates proof-of-concept feasibility for drone-compatible organ transport. UAV-enabled logistics may complement existing organ transport systems by reducing delays associated with traffic congestion and coordination challenges. Further clinical validation and regulatory approvals are required before routine deployment.